128053-53-2
Chemical Structure
KRI-1314
- CAS No.: 128053-53-2
- Formula:C38H51N5O7
- Molecular Weight:689.84
InChIKey: NQXSBCTYTMQGGJ-ICAZUDSDSA-N
SMILES: CC(C)OC([C@H](O)[C@H](CC1CCCCC1)NC([C@H](CC2=CN=CN2)NC([C@@H](CC(N3CCOCC3)=O)CC4=CC=CC5=C4C=CC=C5)=O)=O)=O
Biological Activity: KRI-1314 is an orally active human renin inhibitor with selectivity for primate renin over non-primate renin. KRI-1314 competitively inhibits the binding of recombinant human renin to its substrate, reduces plasma renin activity, lowers blood pressure, and exhibits high stability in tissue homogenates. KRI-1314 is applicable to research on renin-dependent hypertension and hypertension-related studies[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
KRI-1314 | KRI-1314 is an orally active human renin inhibitor with selectivity for primate renin over non-primate renin. KRI-1314 competitively inhibits the binding of recombinant human renin to its substrate, reduces plasma renin activity, lowers blood pressure, and exhibits high stability in tissue homogenates. KRI-1314 is applicable to research on renin-dependent hypertension and hypertension-related studies. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Etoh Y, et al. KRI-1314: an orally effective inhibitor of human renin. Jpn J Pharmacol. 1993;63(1):109-119. [Content Brief]
- [2]. Doi M, et al. Conformational study of a potent human renin inhibitor: X-ray crystal structure of isopropyl (2R,3S)-4-cyclohexyl-2-hydroxy-3-{N-[(2R)-2-morpholinocarbonylmethyl-3-(1-naphthyl)propionyl]-L-histidylamino}butyrate (KRI-1314), a pentapeptide analogue with amino acid sequence corresponding to the cleava. J Chem Soc Perkin Trans 1. 1991:1153-1158.
- [3]. Shibasaki M, et al. The effect of intravenous recombinant human renin on blood pressure in pithed spontaneously hypertensive rats. Eur J Pharmacol. 1992;215(2-3):271-276. [Content Brief]
